Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NERV Minerva Neurosciences

Trading 05-06 12:41:47 EDT

6.18

-0.07

-1.12%

High6.33	Low6.07	Vol38.57K
Open6.31	D1 Closing6.25	Amplitude4.08%
Mkt Cap270.94M	Tradable Cap33.60M	Total Shares43.84M
T/O239.64K	T/O Rate0.71%	Tradable Shares5.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NERV","market":"US","secType":"STK","nameCN":"Minerva Neurosciences","latestPrice":6.18,"timestamp":1778085673806,"preClose":6.25,"halted":0,"volume":38571,"delay":0,"changeRate":-0.011200000000000045,"floatShares":5437017,"shares":43842000,"eps":-34.67,"marketStatus":"Trading","change":-0.07,"latestTime":"05-06 12:41:47 EDT","open":6.31,"high":6.325,"low":6.07,"amount":239644.940106,"amplitude":0.0408,"askPrice":6.19,"askSize":103,"bidPrice":6.16,"bidSize":111,"shortable":3,"etf":0,"ttmEps":-34.67,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778097600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1404187200000,"exchange":"NASDAQ","adjPreClose":6.25,"preHourTrading":{"tag":"盘前","latestPrice":6.28,"preClose":6.25,"latestTime":"09:28 EDT","volume":174,"amount":1070.999928,"timestamp":1778074081092,"change":0.03,"changeRate":0.0048,"amplitude":0.0384},"postHourTrading":{"tag":"盘后","latestPrice":6.25,"preClose":6.25,"latestTime":"18:38 EDT","volume":559,"amount":3491.18,"timestamp":1778020684469,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.684223,"impliedVol":4.114,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NERV","defaultTab":"news","newsList":[{"id":"2633910012","title":"Minerva Neurosciences Q1 Adj. EPS $(0.17) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910012","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910012?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:17","pubTimestamp":1777983428,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 66 percent increase over losses of $(0.50) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52279405/minerva-neurosciences-q1-adj-eps-0-17-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103989","title":"Minerva Neurosciences Q1 net loss widens to $125.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103989","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103989?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982443,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences posted a GAAP net loss of USD 125.4 million, or USD 2.86 per share, for first-quarter 2026, versus a net loss of USD 3.8 million, or USD 0.50 per share, a year earlier.Operating loss widened to USD 16.7 million as R&D expenses climbed to USD 5.3 million from USD 1.4 million; G&A expenses rose to USD 11.4 million from USD 2.5 million.Loss was weighed by a non-cash expense of USD 109.4 million tied to changes in fair value of warrant liability and losses on warrant exercises.Cash, cash equivalents, marketable securities, restricted cash totaled USD 78.2 million at March 31, down from USD 82.4 million at Dec. 31.Roluperidone confirmatory Phase 3 trial for negative symptoms of schizophrenia began in first quarter, with first patient screened in March; topline efficacy data expected in second half of 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL6ZZJgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014039.USD","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","BK4588","LU2095319765.USD","NDAQ","NERV","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910436","title":"Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910436","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910436?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982400,"startTime":"0","endTime":"0","summary":"Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–dr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/Minerva-Neurosciences-Provides-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","PSP","BK4139","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629655073","title":"Minerva Neurosciences files Form 3 for Chief Business Officer and GC James Joseph O'Connor","url":"https://stock-news.laohu8.com/highlight/detail?id=2629655073","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629655073?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:54","pubTimestamp":1776891267,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences reported an initial Form 3 filing for James Joseph O'Connor, chief business officer and general counsel, dated April 21, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5cSk7z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627870412","title":"Minerva Neurosciences Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2627870412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627870412?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:29","pubTimestamp":1776259740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NERV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 15, 2026 09:29 ET (13:29 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627340273","title":"Minerva initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2627340273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627340273?lang=en_us&edition=fundamental","pubTime":"2026-04-15 16:40","pubTimestamp":1776242430,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of Minerva (NERV) with an Outperform rating and $14 price target Minerva is developing roluperidone for the treatment o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/minerva-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/minerva-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NERV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625604494","title":"Minerva Neurosciences announces upcoming annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625604494","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625604494?lang=en_us&edition=fundamental","pubTime":"2026-04-07 05:08","pubTimestamp":1775509713,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences scheduled its 2026 annual meeting of stockholders for June 3, 2026 in Burlington, Massachusetts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLbQsql4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624680204","title":"Minerva Neurosciences Appoints New Chief Business Officer, Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2624680204","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624680204?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:51","pubTimestamp":1775166665,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences ( ($NERV) ) has shared an update. On March 30, 2026, Minerva Neurosciences reached a settlement agreement with longtime execu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-appoints-new-chief-business-officer-counsel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-appoints-new-chief-business-officer-counsel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NERV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624684020","title":"Minerva appoints Jim O'Connor chief business officer as President Geoff Race exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684020","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624684020?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160355,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences named Jim O’Connor Chief Business Officer, effective April 21, 2026.O’Connor will also serve as General Counsel.President Geoff Race will leave company, remaining involved as a consultant.Race joined Minerva in 2010, serving in roles including Chief Financial Officer and Chief Business Officer before becoming President.Executive Chairman and CEO Remy Luthringer said O’Connor will help advance roluperidone toward next planned Phase 3 trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1MTJKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","BK4139","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4588","BK4585","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","NERV","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624071684","title":"Press Release: Minerva Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2624071684","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624071684?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160300,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass., April 02, 2026  -- Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer , effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant.Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President. Over his 16 years with the Company, he played a central role in establishing Minerva's operational, financial, and clinical development foundation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","CEO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537195","title":"Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537195","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537195?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3266016/32445/en/Minerva-Neurosciences-Announces-First-Patient-Screened-in-Global-Phase-3-Confirmatory-Trial-of-Roluperidone-for-the-Treatment-of-Negative-Symptoms-of-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","PSP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004960","title":"Minerva Neurosciences presents open-label safety trial data; roluperidone-olanzapine co-administration shows no safety concerns at SIRS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004960","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004960?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469144,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences presents open-label safety trial data; roluperidone-olanzapine co-administration shows no safety concerns at SIRS 2026. Minerva reported clinical data from an open-label safety trial evaluating roluperidone co-administered with olanzapine in patients with schizophrenia and moderate to severe negative symptoms.The results were presented at the 2026 Schizophrenia International Research Society Annual Congress and included safety, pharmacokinetic, and pharmacodynamic findings.The company said the trial showed no clinically significant adverse effects and no meaningful pharmacokinetic changes during combined administration.Minerva also said a confirmatory Phase 3 trial is enrolling, with topline data anticipated in the second half of 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL7HBxBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4139","IE00B3QW5Z07.USD","SG9999014013.SGD","NERV","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4588","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619780458","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619780458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619780458?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:01","pubTimestamp":1773648076,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dianthus Therapeutics (DNTH – Research Report) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-minerva-neurosciences-nerv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4581","LU0029874061.USD","XBI","XLV","BK4137","NERV","DNTH","LABU","BK4139","LU0128526141.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131818","title":"Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131818?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:38","pubTimestamp":1773315480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NERV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 12, 2026 07:38 ET (11:38 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618353136","title":"Minerva Neurosciences to Present at Stifel Virtual CNS Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2618353136","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618353136?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:01","pubTimestamp":1773313292,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences to Present at Stifel Virtual CNS Forum               Minerva will participate in the Stifel 2026 Virtual CNS Forum on March 17-18, 2026. Remy Luthringer is scheduled to give a co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL9yWHSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","BK4588","BK4585","NERV","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618189852","title":"U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618189852?lang=en_us&edition=fundamental","pubTime":"2026-03-12 15:49","pubTimestamp":1773301752,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum.March 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Thursday, includi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4N4000M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORCX","COHR","CIEN","BMBL","BX","LITX","EXOD","MU","EOG","ORCL","CTRA","NEM","JBL","DOW","ORCS","NERV","FCXG","IBRX","NEMG","GIS","CZR","DVN","ORCU","AVAV","CE","MUR","FPI","MOH","FCX","LITE","AVXX","LEA","FANG","AVBP","EMN","MUD","CHRD","OLN","AESI","NTSK","ANET","CENX","HL","AU","PENN","APA","ATO","MUU","CAG","OXY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618290086","title":"Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2618290086","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618290086?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:01","pubTimestamp":1773295261,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences (NERV) has disclosed a new risk, in the Share Price & Shareholder Rights category. Minerva Neurosciences faces significant di...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-warns-of-major-dilution-risk-from-preferred-stock-conversions-and-warrant-exercises?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-warns-of-major-dilution-risk-from-preferred-stock-conversions-and-warrant-exercises?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NERV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618940715","title":"Minerva Neurosciences Inc - May Offer up to $200 Mln of Securities in Multiple Offerings - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940715?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:21","pubTimestamp":1773235273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ10L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618941509","title":"Minerva Neurosciences Q4 Adj. EPS $(0.64) Misses $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941509","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941509?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:25","pubTimestamp":1773228312,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.30) by 113.33 percent. This is a 14.29 percent decrease over losses of $(0.56) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51182247/minerva-neurosciences-q4-adj-eps-0-64-misses-0-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618949570","title":"Minerva Neurosciences Q4 net loss widens to USD 283.7 million as total liabilities jump more than tripled to USD 233.76 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618949570","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618949570?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:02","pubTimestamp":1773226935,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences Q4 net loss widens to USD 283.7 million as total liabilities jump more than tripled to USD 233.76 million. Minerva reported a GAAP net loss of USD 283.67 million for Q4 2025, compared with a GAAP net loss of USD 4.27 million a year earlier, driven mainly by a USD 321.5 million non-cash loss on issuance of convertible preferred stock and warrants. R&D expense in Q4 2025 rose 10% to USD 2.17 million, primarily due to higher consultant fees, while G&A expense increased 11% to USD 2.81 million, mainly due to higher compensation expenses partially offset by lower insurance costs. For FY 2025, Minerva posted a GAAP net loss of USD 293.42 million versus GAAP net income of USD 1.44 million in FY 2024, while non-GAAP adjusted net loss narrowed 17% to USD 15.99 million. Cash, cash equivalents and restricted cash totaled USD 82.4 million at Dec. 31, 2025, up nearly quadruple from a year earlier, following USD 80 million in gross proceeds from an October 2025 private placemen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL3JTyDj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","NDAQ","SG9999014013.SGD","LU2210150020.SGD","BK4139","NERV","IE00B64PRP62.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minervaneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.0295},{"period":"1month","weight":0.1837},{"period":"3month","weight":0.3383},{"period":"6month","weight":0.717},{"period":"1year","weight":2.655},{"period":"ytd","weight":0.5547}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.082044},{"month":2,"riseRate":0.25,"avgChangeRate":-0.062323},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.006398},{"month":4,"riseRate":0.5,"avgChangeRate":0.052093},{"month":5,"riseRate":0.5,"avgChangeRate":0.131641},{"month":6,"riseRate":0.636364,"avgChangeRate":0.069702},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.035509},{"month":8,"riseRate":0.5,"avgChangeRate":0.304921},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003875},{"month":10,"riseRate":0.25,"avgChangeRate":-0.122814},{"month":11,"riseRate":0.5,"avgChangeRate":0.078313},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.079275}],"exchange":"NASDAQ","name":"Minerva Neurosciences","nameEN":"Minerva Neurosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Minerva Neurosciences(NERV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Minerva Neurosciences,NERV,Minerva Neurosciences股票,Minerva Neurosciences股票老虎,Minerva Neurosciences股票老虎国际,Minerva Neurosciences行情,Minerva Neurosciences股票行情,Minerva Neurosciences股价,Minerva Neurosciences股市,Minerva Neurosciences股票价格,Minerva Neurosciences股票交易,Minerva Neurosciences股票购买,Minerva Neurosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Minerva Neurosciences(NERV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction